Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

17th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 12th October 2022 (Educational supporters)

siRNA-mediated lowering of Lp(a) by Olpasiran

siRNA-mediated lowering of Lp(a) by Olpasiran

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Michael Koren 

read more »
A new ASO PCSK9 inhibitor: The Etesian study

A new ASO PCSK9 inhibitor: The Etesian study

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Alexis Hofherr 

read more »
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Sotirios Tsimikas 

read more »
siRNA-mediated lowering of Lp(a) by SLN360

siRNA-mediated lowering of Lp(a) by SLN360

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Steve Nissen 

read more »
PCSK9 and diabetes risk

PCSK9 and diabetes risk

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Wilfried Le Goff 

read more »
Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH

Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Albert Wiegman 

read more »
How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors

How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors

Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board  Pia Kamstrup 

read more »